Cross-Clade p17 Peptide Recognition by Antisera to HGP-30, a 30-Amino Acid Synthetic Peptide Antigen from HIV Type 1 p17
- 10 June 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 14 (9) , 741-749
- https://doi.org/10.1089/aid.1998.14.741
Abstract
HGP-30, a 30-amino acid synthetic peptide analog of HIV-1SF2 p17 (aa 86–115), was used to immunize both mice and humans. Since the amino acid sequence of HGP-30 is relatively conserved among different HIV-1 strains and clades, experiments were carried out to determine if antisera obtained by immunizing animals and humans can recognize HGP-30-related peptide consensus sequences belonging to different clades. Results show that antisera from mice immunized with HGP-30 can recognize clade B and C and to a lesser degree clade A and E consensus sequences of HIV-1, in addition to recognizing HGP-30 sequence. The cross-clade recognition was higher in mouse sera obtained on day 42 than on day 14 or 28. MPL/SE and Novasomes were better adjuvants than alum in inducing antibodies that showed cross-clade recognition and IgG2a and IgG2b antibody isotypes. Similar cross-clade recognition was observed in several sera from humans immunized with an HGP-30/KLH/alum formulation. The human sera from HGP-30-immunized subjects evaluated for cross-clade recognition of HGP-30 peptides were from subjects whose cells showed significant protection from HIV infection on virus challenge in the hu-PBL-SCID mouse model. These studies suggest that HGP-30 may be useful as a candidate vaccine antigen for populations in countries with prevalence of different HIV clades.Keywords
This publication has 22 references indexed in Scilit:
- Memory Cytotoxic T Lymphocyte Responses in Human Immunodeficiency Virus Type 1 (HIV-1)-Negative Volunteers Immunized with a Recombinant Canarypox Expressing gp160 of HIV-1 and Boosted with a Recombinant gp160The Journal of Infectious Diseases, 1996
- A Dose-Ranging Study of a Prototype Synthetic HIV-1MN V3 Branched Peptide VaccineThe Journal of Infectious Diseases, 1996
- Toward an Understanding of the Correlates of Protective Immunity to HIV InfectionScience, 1996
- HIV Preventive VaccinesDrugs, 1995
- Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.The Journal of Experimental Medicine, 1995
- Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infectionJournal of Molecular Recognition, 1993
- Scientific and Social Issues of Human Immunodeficiency Virus Vaccine DevelopmentScience, 1993
- A TH1→TH2 switch is a critical step in the etiology of HIV infectionImmunology Today, 1993
- Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLHInternational Journal of Immunopharmacology, 1991
- Cytotoxic T lymphocytes against HIVAIDS, 1990